| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712598.2013.754420 |
| P698 | PubMed publication ID | 23228025 |
| P2093 | author name string | Mark Stacy | |
| Patrick Hickey | |||
| P2860 | cites work | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 |
| Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum | Q44631221 | ||
| Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up | Q44995599 | ||
| Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. | Q45859568 | ||
| Medical treatment of Parkinson disease. | Q45952832 | ||
| Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease | Q48184014 | ||
| Sequential bilateral transplantation in Parkinson's disease: effects of the second graft | Q48194358 | ||
| Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys | Q48197305 | ||
| Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys | Q48325968 | ||
| Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? | Q48390998 | ||
| Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease | Q48405897 | ||
| A randomized trial of deep-brain stimulation for Parkinson's disease | Q48433139 | ||
| Dopaminergic differentiation of neural progenitors derived from placental mesenchymal stem cells in the brains of Parkinson's disease model rats and alleviation of asymmetric rotational behavior | Q48493117 | ||
| Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease | Q48671006 | ||
| Acute and Long-Term Effects of Subthalamic Nucleus Stimulation in Parkinson's Disease | Q51647407 | ||
| Neurturin, a relative of glial-cell-line-derived neurotrophic factor | Q24324692 | ||
| GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons | Q24336322 | ||
| Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial | Q28296434 | ||
| Axonal transport defects: a common theme in neurodegenerative diseases | Q28302119 | ||
| AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 | ||
| AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial | Q28307713 | ||
| Transplantation of embryonic dopamine neurons for severe Parkinson's disease | Q29617304 | ||
| Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases | Q33542013 | ||
| Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys | Q33819946 | ||
| Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial | Q33870490 | ||
| Results from a phase I safety trial of hAADC gene therapy for Parkinson disease | Q34656075 | ||
| Bilateral transplantation of allogenic adult human bone marrow-derived mesenchymal stem cells into the subventricular zone of Parkinson's disease: a pilot clinical study | Q35893878 | ||
| Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells | Q36288360 | ||
| Levodopa for the treatment of Parkinson's disease | Q37340190 | ||
| Restorative approaches in Parkinson's Disease: which cell type wins the race? | Q37592613 | ||
| Axonal transport defects in neurodegenerative diseases | Q37614744 | ||
| Towards stem cell replacement therapies for Parkinson's disease | Q37759814 | ||
| Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinson's disease | Q37872232 | ||
| Neurotrophic molecules | Q38721363 | ||
| Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. | Q39507945 | ||
| Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease | Q39518245 | ||
| Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease | Q39519102 | ||
| Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. | Q39782948 | ||
| Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease | Q39863620 | ||
| Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease | Q40197232 | ||
| Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. | Q40273125 | ||
| Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease | Q40326219 | ||
| Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. | Q40678042 | ||
| Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease | Q40737427 | ||
| Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor | Q40843723 | ||
| Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease | Q40846012 | ||
| Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease | Q40929764 | ||
| Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. | Q41031978 | ||
| Dopaminergic neurons protected from degeneration by GDNF gene therapy | Q41128316 | ||
| Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases | Q41195395 | ||
| Pharmacology of neurotrophic factors | Q41455744 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial | Q42650874 | ||
| Parkinson's disease, primates, and gene therapy: vive la différence? | Q42719725 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 137-145 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | AAV2-neurturin (CERE-120) for Parkinson's disease | |
| P478 | volume | 13 |
| Q99584192 | CERE-120 Prevents Irradiation-Induced Hypofunction and Restores Immune Homeostasis in Porcine Salivary Glands |
| Q35472697 | Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration |
| Q47162932 | Neurturin overexpression in dopaminergic neurons induces presynaptic and postsynaptic structural changes in rats with chronic 6-hydroxydopamine lesion |
| Q39229450 | Non-human primate models of PD to test novel therapies |
| Q35183919 | Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson's disease patients |
| Q38121120 | Small RNA drugs for prion disease: a new frontier |
| Q38136096 | Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases |
| Q42094999 | The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions |
Search more.